EVITA: Evaluation of VIP Feature in Pacemaker Patients
1 other identifier
interventional
461
2 countries
2
Brief Summary
The primary efficacy objective of this clinical investigation is to demonstrate that the Ventricular Intrinsic Preference (VIP™) feature allows to reduce the medium- and long-term incidence of unnecessary ventricular pacing in patients with intact AV conduction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2006
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 18, 2006
CompletedFirst Posted
Study publicly available on registry
August 21, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedFebruary 4, 2019
February 1, 2019
2.8 years
August 18, 2006
February 1, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of ventricular pacing
6 and 12 months
Study Arms (2)
1
EXPERIMENTALVentricular Instrinsic Preference (VIP) turned ON
2
ACTIVE COMPARATORVentricular Instrinsic Preference (VIP) turned OFF
Interventions
Eligibility Criteria
You may qualify if:
- Patient has an indication for implantation of a dual-chamber pacemaker;
- Patient is implanted or scheduled to be implanted with a St Jude Medical Victory pacemaker, or newer device with the same study relevant feature.
You may not qualify if:
- Patient has persistent or permanent AF/AFl;
- Patient has permanent AV Block;
- Patient has a pacemaker replacement;
- Patient is in NYHA class IV;
- Patient is unable to attend the follow-up visits;
- Patient is pregnant;
- Patient is less than 18 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Universitätskliniken Heidelberg
Heidelberg, 69115, Germany
Sahlgrenska University Hospital
Gothenburg, 413 45, Sweden
Related Publications (1)
Bauer A, Vermeulen J, Toivonen L, Voitk J, Barr C, Peytchev P. Minimizing right ventricular pacing in pacemaker patients with intact and compromised atrioventricular conduction : Results from the EVITA Trial. Herzschrittmacherther Elektrophysiol. 2015 Dec;26(4):359-66. doi: 10.1007/s00399-015-0394-2. Epub 2015 Aug 28.
PMID: 26315154DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Alexander Bauer, MD
Universitätskliniken Heidelberg, Heidelberg, 69115, Germany
- PRINCIPAL INVESTIGATOR
Charles Kennergren, MD
Sahlgrenska University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 18, 2006
First Posted
August 21, 2006
Study Start
August 1, 2006
Primary Completion
June 1, 2009
Study Completion
September 1, 2010
Last Updated
February 4, 2019
Record last verified: 2019-02